Lung cancer incidence and mortality in relationship to hormone replacement therapy use among women participating in the PLCO trial: a post hoc analysis

2020 ◽  
Vol 25 (5) ◽  
pp. 885-891 ◽  
Author(s):  
Omar Abdel-Rahman
2020 ◽  
Vol 159 (4) ◽  
pp. 1546-1556.e4 ◽  
Author(s):  
Ashley L. Titan ◽  
Hao He ◽  
Natalie Lui ◽  
Douglas Liou ◽  
Mark Berry ◽  
...  

2006 ◽  
Vol 12 (1_suppl) ◽  
pp. 8-10 ◽  
Author(s):  
John C Stevenson

Drospirenone is a new progestogen in hormone replacement therapy, with anti-mineralocorticoid activity. This anti-mineralocorticoid activity counteracts water and sodium retention, helping to reduce the likelihood of fluid retention that some women experience with hormone replacement therapy. In a post hoc analysis of women with mild hypertension, estradiol (1 mg) plus drospirenone (2 mg) was found to lower blood pressure in mildly hypertensive women. The introduction of estradiol plus drospirenone may offer the opportunity to re-evaluate the contribution of the progestogen component of hormone replacement therapy.


The Lancet ◽  
2010 ◽  
Vol 375 (9709) ◽  
pp. 118-119 ◽  
Author(s):  
Rowan T Chlebowski ◽  
Ann G Schwartz ◽  
Heather Wakelee ◽  
Garnet L Anderson

Sign in / Sign up

Export Citation Format

Share Document